• Coupon Patent Easily Found Invalid under § 101

    By Joseph Herndon —

    District Court for the District of DelawareOn January 12, 2016, the District Court for the District of Delaware issued an opinion in a case captioned Motivation Innovations, LLC v. Petsmart, Inc.  Plaintiff, Motivation Innovations, LLC, filed a patent infringement action against defendant Petsmart Inc. alleging infringement of U.S. Patent No. 5,612,527, and defendant filed a motion for judgment on the pleadings asserting that the '527 is invalid under 35 U.S.C. § 101 as being directed to an abstract idea without significantly more.

    The District Court granted the Defendant's motion for judgment on the pleadings, and found the '527 patent invalid under 35 U.S.C. § 101.

    The '527 patent, titled "Discount Offer Redemption System and Method," was filed on March 31, 1995, and issued on March 18, 1997.  An ex parte reexamination of the '527 patent was completed on April 27, 2010 with original claims 1-16 confirmed, original claims 17-20 confirmed with amendment (or depending from an amended claim), and new claims 21-39 allowed.

    District Court's thoughts on § 101 Challenges

    The District Court followed the two-prong test for distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.  First, we determine whether the claims at issue are directed to one of those patent-ineligible concepts.  If so, we then ask, "[w]hat else is there in the claims before us?"  The second prong has become known as a search for an "inventive concept" — i.e., an element or combination of elements that is "sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself."

    The District Court summarized many Federal Circuit cases covering § 101 law including DDR Holdings, Ultramercial, and the Intellectual Ventures cases.  The District Court expressed its confusion with the current state of the law, and stated that in reviewing post-Alice cases, "the court is struck by the evolution of the § 101 jurisprudence, from the complete rejection of patentability for computer programs to the almost complete acceptance of such, to the current (apparent) requirements that the patent claims in suit (1) disclose a problem 'necessarily rooted in computer technology,' and (2) claim a solution that (a) not only departs from the 'routine and conventional' use of the technology, but (b) is sufficiently specific so as to negate the risk of pre-emption."

    The District Court noted that even though most of the patent claims now being challenged under § 101 would have survived such challenges if mounted at the time of issuance, these claims are now in jeopardy under the heightened specificity required by the Federal Circuit post-Alice.

    The District Court offered a further opinion that "it is less than clear how a § 101 inquiry that is focused through the lens of specificity can be harmonized with the roles given to other aspects of the patent law (such as enablement under § 112 and non-obviousness under § 103), especially in light of the Federal Circuit's past characterization of § 101 eligibility as a 'coarse' gauge of the suitability of broad subject matter categories for patent protection."

    The District Court continued, complaining that:

    Given the evolving state of the law, the § 101 analysis should be, and is, a difficult exercise.  At their broadest, the various decisions of the Federal Circuit would likely ring the death-knell for patent protection of computer-implemented inventions, a result not clearly mandated (at least not yet).  On the other hand, to recognize and articulate the requisite degree of specificity — either in the equipment used or the steps claimed — that transforms an abstract idea into patent-eligible subject matter is a challenging task.  In trying to sort through the various iterations of the § 101 standard, the court looks to DDR as a benchmark; i.e., the claims (informed by the specification) must describe a problem and solution rooted in computer technology, and the solution must be (1) specific enough to preclude the risk of pre-emption, and (2) innovative enough to "override the routine and conventional" use of the computer.  DDR, 773 F.3d at 1258-59.  The pre-emption concern is generally amenable to review in the context of a motion to dismiss or for judgment on the pleadings.  The second requirement, which may well involve issues of fact relating to the state of the art in the technological environment involved, is more appropriately addressed after discovery in the context of a motion for summary judgment.

    I think a number of practitioners echo the sentiments of the District Court, and find the Federal Circuit's handling of § 101 challenges confusing and inconsistent, at best.

    The '527 patent

    The '527 patent discloses and claims methods for redeeming discount offers by associating a machine-readable identification code, such as a barcode, with data identifying items to be offered at a discount.  The data is stored in a database in memory, and the discount is provided for those items for which data is listed in the database.  Independent claim 1 recites:

    1.  A method for redeeming discount offers comprising:
        providing a circulation medium and providing said medium with indicia which includes a machine readable identification code;
        causing said medium to be distributed to potential users;
        associating said identification code with data identifying items which are to be offered at a discount provided as part of said medium and storing said data in memory in a data base so as to be addressable by said identification code;
        providing means for reading said identification code provided with said circulation medium;
        providing means associated with said code reading means for tabulating sales of items so that any discount corresponding to an item listed in said data is deducted from the price of the item in the tabulation; and
        using said reading means to identify said code provided with said medium and using said means for tabulating items to obtain a price for the involved item and to cause a discount to be debited against the purchased item if the involved item is listed as part of said data identifying an item as qualifying for a discount as called for by the data base data defined by the identification code of the medium.

    Independent claim 17 slightly differs from claim 1 and recites "A method of tracking customer purchasing habits," with the differing claim functions including:

        providing means for tabulating items and for recording the items purchased by the bearer of the circulation medium and providing means for calculating the at least one discount on the item offered at discount by said identification code means; and
        tabulating items purchased and storing a record of the tabulated items in said data file identified by the identification code means thereby enabling tracking of purchasing habits of individuals who receive and use the circulation medium.

    The '527 specification describes that a point of sale ("POS") machine uses the indicia on the flyers "to identify items which are offered at a discount and then apply an appropriate credit to the purchased items."  Moreover, each point of sale machine is linked to a main computer which includes a controller responsible for managing the data which is input to the system through the point of sale machines as part of the normal transactions of the store.  The point of sale machines are standard readily available machines each having a microcomputer unto themselves which is capable of communicating in real time with the main computer of the network.

    § 101 Analysis

    Applying the analytical framework of Alice, the District Court first determined that the claims at issue are directed to an abstract idea of using coupons to provide discounts.  Regardless of the extra limitations related to how the method is used or what it improves, the patent claims are simply directed to the "use and redemption" of coupons.

    Turning to step two of the Alice framework, the District Court found that the additional limitations of the asserted claims recite conventional or routine activity or computer technology.  For example, creating and distributing a circulation medium (e.g., brochure) having a UPC bar-code is conventional activity, and associating bar-codes with a data file and using a generic bar-code scanner to scan the bar-code as well as using a generic point-of-sale machine include use of generic/known computer devices.  In fact, the '527 specification explains that the POS machine is a "standard readily available machine," with a microcomputer capable of communicating in real time with the main computer of the network.  No special programming is disclosed.

    The Plaintiff describes the '527 patent as disclosing a particular and specific method and system for the use and redemption of "discount offers" (or coupons) that reduced the need for consumers and retailers to handle and process large quantities of coupons, reduced fraud, and allowed retailers to keep track of purchases made by individual consumers.  The Plaintiff's main argument was that the invention is novel because it had not been previously known to use a single coupon with one "indicia" to redeem offers on multiple products, or to create and use a database of individual customer's purchasing history while doing so.

    But, the District Court, following its understanding of the application of § 101 law, stated that the inventive concept of using a machine readable identification code to take discount offers and track customer purchasing habits, is not an internet (or computer) centric problem.  The District Court here placed its emphasis on the need for the invention to be necessarily rooted in computer technology so as to survive the § 101 challenge.

    Here, the '527 patent had problems from the beginning.  It is not advised to describe aspects or elements recited in the claims as "standard" or "well-known".  This will only lead to courts finding those items to be routine and conventional computer technology.  In addition, clearly by March 31, 1995 (the filing date of the '527 patent), coupons were in use.  The Plaintiff's only assertion of inventive concept was associating one coupon with discounts on multiple items.  This, though, is difficult to find as an inventive concept.  You can imagine prior art coupons offering discounts on multiple items (i.e., $1 off 2 or more boxes of cereal).  Because the "business method" aspects of the claim were not new, and because the computer elements in the claim only covered generic computer functionality, these claims were doomed by Alice.

  • Business Method Patent Survives PTAB Review

    By Joseph Herndon —

    USPTO SealOn January 22, 2016, the U.S. Patent Trial and Appeal Board (PTAB) issued a decision denying institution of a covered business method (CBM) patent review in a case captioned NRT Technology Corp. and NRT Technologies, Inc. (Petitioner) v. Everi Payments, Inc. (Patent Owner) (Case CBM2015-00167; U.S. Patent No. 6,081,792).

    The PTAB determined that that Petitioner was less likely than not to prevail with respect to all of the challenged claims, and thus, the Petition to institute a CBM patent review was denied.  This is a good sign for business method patent owners to show that business method patents are not outright dead.  There is hope, if the claims are properly drafted.

    The PTAB first noted the requirements for instituting a CBM patent review in that the Director must determine "that the information presented in the petition . . . would demonstrate that it is more likely than not that at least 1 of the claims challenged in the petition is unpatentable."  35 U.S.C. § 324(a).  The threshold for instituting petitions for post grant reviews — codified at 35 U.S.C. § 324(a) — also applies to petitions for CBM patent reviews.  The difference, of course, for a CBM patent review is that the claims challenged must be directed to a financial product or service (and thus, excludes technological inventions), and the Petitioner must be charged with infringement of the patent in order to request a CBM patent review.  Prior to addressing the issue of standing, it is necessary to investigate the scope of the '792 patent.

    The '792 patent subject matter

    The '792 patent describes an interesting function for use of automated teller machines ("ATMs") to issue receipts for a "purchase" that can be cashed in at designated locations for cash of the purchase.

    The '792 patent relates to a modified ATM or terminal that allows a customer to obtain cash from an account via various processes such as an ATM process or a point-of-sale ("POS") process using both debit cards and credit cards.  In its "Description of the Prior Art," the '792 patent notes two so-called problems associated with obtaining cash from prior art ATMs (i.e., via an ATM network).  First, with respect to using a debit/ATM card, a bank typically imposes a daily limit on ATM cash withdrawals.  Second, with respect to using a credit card to obtain cash from an ATM, the '792 patent blames people for often not knowing the personal identification number ("PIN") that is required because they may not regularly use a credit card for that purpose.

    According to the '792 patent, neither of these problems is encountered when using the same cards to make purchases, which occur over a POS network, not an ATM network.  With respect to debit/ATM cards, "one can reach [his] ATM limit and not be able to obtain more cash that day from an ATM, but will still be able to purchase goods and services via a point-of sale transaction because of the distinct and separate limit for point-of-sale transactions."  With respect to credit cards, the '792 patent states that PINs are not typically required to make purchases. (However, while not described in the '792 patent, as credit cards change over to the Chip-enabled technology, many credit card companies are requiring use of PINs).

    The '792 patent describes and claims methods of using a modified ATM or terminal that can access a bank via both an ATM network and a POS network.  Figure 2 is reproduced below.

    FIG2
    The '792 patent describes a method of using a modified ATM such as the terminal depicted in Figure 2, in which a cardholder first attempts to obtain money via a first type of transaction (i.e., conducted over an ATM network) and fails because he has exceeded his ATM daily limit or he cannot remember the PIN for his credit card and subsequently and successfully obtains money via a second type of transaction (i.e., conducted via a POS network).

    But, the cardholder does not obtain cash (or other valuable item) directly from the terminal when using the POS network.  Instead, the terminal informs a nearby money location (such as "cash windows or 'cages' within casinos or racetracks, front desks or concierges of hotels, ticket booths, will-call windows or customer service windows at stadiums, coliseums, theaters, stores, or amusement parks") of the approved transaction.  The terminal may also issue a "script" or "pre-receipt" for the cardholder to take to the money location.  At the money location, the cardholder cashes in the receipt for the cash.  In the preferred embodiment, a check drawn against the cardholder's account is issued at the money location and made payable to the money location owner.

    The challenged claims

    Of the challenged claims, claim 1 is illustrative and reproduced below.

    1.  A method of providing money or an item of value to an account-holder, the method comprising:
        identifying an account to a terminal;
        entering a personal identification number into the terminal;
        requesting money or an item of value based upon the account via a first type of transaction;
        forwarding the first type of transaction to a processor;
        forwarding the first type of transaction from the processor to a first network;
        forwarding the first type of transaction from the first network to a bank;
        making a denial of the first type of transaction due to exceeded pre-set limit;
        forwarding the denial to the processor;
        notifying the account-holder at the terminal of the denial of the first type of transaction, and asking the account holder if they would like to request the money or item of value via a second type of transaction;
        requesting money or an item of value based upon the account via a second type of transaction;
        forwarding the second type of transaction to the processor;
        forwarding the second type of transaction from the processor to a second network;
        forwarding the second type of transaction from the second network to the bank;
        making an approval of the second type of transaction;
        forwarding the approval to the processor;
        and instructing a money location separate from the terminal to provide money or an item of value to the account-holder.

    In a CBM patent review, the PTAB noted that "[a] claim in an unexpired patent shall be given its broadest reasonable construction in light of the specification of the patent in which it appears."  While the Petitioner proposed express constructions, many of which would require, or at least encompass, human involvement in certain steps of the claimed methods, the PTAB agreed with the Patent Owner that the plain and ordinary meaning is readily apparent.

    Petitioner has standing

    The PTAB addressed the issue of standing, noting that Petitioner has shown that the (1) Petitioner has been sued for infringement of the patent and (2) the patent for which review is sought is a covered business method patent.

    With respect to item (2), a CBM patent is defined as "a patent that claims a method or corresponding apparatus for performing data processing or other operations used in the practice, administration, or management of a financial product or service, except that the term does not include patents for technological inventions."  This requirement has two prongs: (i) that all of the claims are directed to methods used in conducting financial transactions and (i) that the patent is not for a technological invention.

    To determine whether a patent is for a technological invention, the PTAB considers "whether the claimed subject matter as a whole": (1) "recites a technological feature that is novel and unobvious over the prior art"; and (2) "solves a technical problem using a technical solution."  37 C.F.R. § 42.301(b).

    The Petitioner argued that "all of the claimed features that could possibly be characterized as technological (i.e., terminal, processor, ATM network, POS network) were present in the prior art."  The Patent Owner disputed this position, and asserted that the software had a technological feature of "asking the account holder if they would like to request the money or item of value via a second type of transaction."  But, the PTAB found that displaying declaratory and interrogatory data on a display and soliciting a response thereto is not a technological feature that is novel.

    Further, the PTAB noted that the problem in the prior art which the '792 patent sets out to solve — "obtaining cash from one's account when their daily ATM limit has been reached" — is not a technical problem.  Thus, the PTAB found that the '792 patent is a covered business method patent that is eligible for CBM patent review.

    Patent-ineligibility

    The Petitioner challenged the claims as patent-ineligible under 35 U.S.C. § 101.  The PTAB noted the Supreme Court's framework for distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.  First, it is determined whether the claims at issue are directed to one of those patent-ineligible concepts.  If so, we then ask, "what else is there in the claims before us?"  This second step has become known as a search for an inventive concept — i.e., an element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself.

    The Petitioner did not identify directly "the abstract ideas" to which the claims are purportedly directed.  But, the Petitioner implicitly identified them as:  "providing money to an account holder" and "trial-and-error."

    The PTAB found that the Petitioner oversimplified the challenged claims because the challenged claims are not directed simply to the idea of providing money to an account holder or using trial-and-error until success is achieved.  Rather, the claims are directed to particular methods of providing money to an account holder using an ATM via a POS transaction after an ATM transaction has failed.

    Further, Petitioner's analysis omits any consideration of the elements of the claims as ordered combinations to determine whether the additional elements transform the nature of the claims into a patent-eligible application.  The PTAB found that it was Petitioner's burden to do so.  Failing to meet this burden, the Petitioner was unable to show that the claims are more likely than not patent-ineligible.

    Other grounds asserted in the Petition included prior art challenges, which also failed and are not discussed in detail here.  Because the information presented in the Petition did not demonstrate that it is more likely than not that any of the claims challenged is unpatentable, the Petition for instituting a CBM patent review was denied and no trial will be instituted.

    This decision represents a rare instance in which a patent found to be directed to a "business method" was also found to satisfy § 101, at least with respect to the basic challenges presented.  It may be the case that the Petitioner did not prepare a solid challenge, and likely did not do itself any favors by failing to directly identify "the abstract ideas" in the claims.  However, on their face, the claims appear to recite enough details to withstand a § 101 challenge.

    This case also shows, what is seeming to become the best way to counter a § 101 challenge, that when the elements of the claims are considered as ordered combinations, there is a better chance to show that the "additional elements" not identified as the abstract idea transform the nature of the claims into a patent-eligible application.  This idea of ordered combinations of the elements makes it clear that when the claim is drafted tying each element together or showing that a subsequent element depends upon outcomes of a prior element, it is more difficult to pick apart the claim in a piecemeal manner.  Following, it is more difficult to identify and remove a so-called "abstract idea" from the claim leaving only wreckage that is insubstantial generic computing components that are always found to fail the inventive concept test.  Thus, using proper claim drafting techniques, "ordered combinations" of elements are a great tool to have to combat a § 101 challenge.

  • By Michael Borella —

    District Court for the Eastern District of TexasIn February 2015, Advanced Marketing Systems (AMS) sued a number of defendants, alleging infringement of various claims of U.S. Patent Nos. 8,219,445, 8,370,199, and 8,538,805.  The defendants filed a motion for judgment on the pleadings, arguing that the case should be dismissed because the asserted claims are directed to non-statutory subject matter under 35 U.S.C. § 101.

    Claim 1 of the '805 patent recites:

    A data processing system for tracking and processing a plurality of in-store discounts to potential purchasers of plural products during the checkout process, wherein said discounts are each associated with a specific one of said plural products, said system comprising:
        a discount vehicle, characterized by two or more of said discounts, including descriptive material to provide information at least identifying the products and their associated discounts;
        a customer account associated with a customer identification code, the customer account comprising two or more of said discounts of the discount vehicle selected by a customer to be associated with the customer account, the customer account being associated with a select code that permits tracking of said customer account during checkout, said select code uniquely identifying all the discounts for all of the plural products associated with the customer account;
        wherein the customer identification code is inputted by the customer to access the customer account;
        a checkout processing terminal including computer based tracking of individual purchasers' purchased products and the prices thereof, wherein said processing terminal includes a device for receiving the select code during checkout; and
        a data processor attached to said checkout terminal for receiving information regarding transactions associated with checkout, selected products and the discounts associated with the select code forming a part of the transactions, and processing said discounts in accord with said select code;
        wherein said data processor selectively deactivates the select code for only particular discounts, of the plurality of discounts, associated with the purchased products by redemption of the select code associated with the customer account such that the select code remains active for future use with yet unused ones of the plurality of discounts associated with said plural products, said data processor being further connected to memory for storing data associated with said transaction.

    Claim 28 of the '199 patent is similar in terms of structure and content.  Further, claim 9 of the '445 patent and claim 15 of the '199 are similar in content, but differ in structure.  Of note are the preambles of these latter two claims, which recite:

    A distributed discount vehicle for use with a data processing system for tracking and processing a plurality of in-store discounts to potential purchasers of plural products during the checkout process, wherein said discounts are each associated with a specific one of said plural products, said discount vehicle comprising . . .

    In order to rule on the motion, the Court applied the now-familiar patent-eligibility test from Alice Corp. v. CLS Bank Int'l.  First, one must determine whether the claim at hand is directed to a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then one must further determine whether any element, or combination of elements, in the claim is sufficient to ensure that the claim amounts to something more than the judicial exception.  Notably, generic computer implementation of an otherwise abstract process does not qualify as "something more."

    The defendants asserted that the claims were directed to the abstract idea of offering, tracking, and processing discounts, a "longstanding commercial practice."  According to the defendants, the claimed features "constitute nothing more than the idea of tracking discounts after they are offered to consumers and processing them once they have been redeemed."  The defendants further contended that "inclusion of elements such as a customer account, a customer identification code, a checkout processing terminal, a data processor, and memory in the claims does not change the basic character of the subject matter of the claims because each function performed by these components is purely conventional."  Thus, in the defendant's view, the claimed invention was merely a mental process that "can be performed by a human using pencil and paper."  To support these positions, defendants alleged that the claimed discount vehicle was "merely an insert in a newspaper or a magazine."

    AMS responded by arguing that the "underlying factual disputes concerning the scope of the claim language make a decision on the issue of patentable subject matter inappropriate at this stage in the case."  AMS disagreed that the discount vehicle was limited to printed information, and asserted that the data processor was "a non-generic, specifically programmed system that selectively deactivates certain e-coupons redeemed by a customer at checkout."  Finally, AMS took the position that selectively applying discounts as claimed was an inventive concept that satisfies the second prong of Alice.

    The Court considered whether it was appropriate to dismiss this case on the pleadings, and noted that "the issue of patentable subject matter requires a legal analysis that can — and often does — contain underlying factual issues."  Further, "where the parties dispute the scope and meaning of the asserted claims as they do here, application of the principles governing a § 101 analysis is not a straightforward exercise."  Ultimately, the Court found several reasons why the case should not be dismissed at this early stage.

    First, the defendants did not establish "an absence of fact and claim construction issues such that the only plausible reading of the asserted claims is one of patent ineligibility."   Instead, for two terms, "discount vehicle" and "selectively activated," there was a material factual dispute between the parties.  Particularly, the defendants' position that the claims were invalid required adopting the defendant's interpretation of these claim terms, which was at odds with the proposed construction offered by AMS.

    Second, the Court found that a reading of the claims did not clearly show that they recite a mere abstraction.  Instead, the Court wrote that "discount vehicle claims, for example, include physical structures such as a discount vehicle with information identifying products and their associated discounts, and a select code that can be selectively deactivated as to certain discounts, while remaining active for future use as to others."  Further, "[t]he data processing system claims recite, in part, a checkout processing terminal with computer based tracking of purchased products and a device for receiving the select code during checkout."  The presence of such physical structures resulted in the Court concluding that "it is impossible to make a final determination before claim construction that the claims are simply a drafting effort designed to monopolize an abstract idea, rather than a patent-eligible application of the idea."

    Third, the parties' dispute over whether the hardware recited by the claims was conventional and generic or specifically programmed, and whether the features associated with the claimed selective deactivation improved upon the prior art, also weighed against a decision on the pleadings.  As a result, the Court concluded that it would deny the defendants' motion without prejudice, thus leaving the defendants open to filing a similar motion after claim construction.

    Standing alone, this case is yet another illustration of how the Alice test could go either way for a given set of claims.  When viewed in light of claims found patent-ineligible by the Federal Circuit and other district courts, AMS's patents could have been easily invalidated on the pleadings.  Particularly, other courts have found financially-oriented transactions to incorporate abstract ideas, and hardware components similar to those at issue here to be merely generic.

    But, this decision takes on a special character when viewed along with Voxathon LLC v. Alpine Electronics of America, Inc., decided by the same judge just a few days earlier.  In Voxathon, the Court held that claim construction was unnecessary before dismissal on the pleadings.  The rub is that AMS's claims appear to be at least as abstract as those in Voxathon, and recite no more specialized hardware components.  Thus, one could argue that either this case, Voxathon, or both were wrongly decided.  At the very least, the outcomes appear to be inconsistent.

    Having said that, the rationale for this apparent discrepancy may be as simple as AMS's arguments being more compelling than those of Voxathon, or that in this case the judge adopted the recommendation of a magistrate, whereas in Voxathon the judge wrote the substantive opinion.  Nonetheless, when viewed on their faces, the two outcomes further illustrate the lack of predictability that pervades the patent system post-Alice.

  • By Andrew Williams —

    Federal Circuit SealBack in January 2002, when this author was near the beginning of his patent law career, the Federal Circuit handed down the In re Sang-Su Lee case.  Among other things, this case provided patent practitioners with support for challenging examiners that failed to identify the evidence on which they were relying.  Before then, the Patent Office would occasionally use the "common knowledge and common sense" of a person of ordinary skill in the art to support obviousness rejections, especially with regard to combining prior art references.  Of course, without any actual evidence provided, it was very difficult to respond to any such rejection.  In re Sang-Su Lee provided the necessary relief:  "The Board cannot rely on conclusory statements when dealing with particular combinations of prior art and specific claims, but must set forth the rationale on which it relies."  Fourteen years later, in Cutsforth Inc. v. MotivePower, Inc., the Federal Circuit told the Patent Trial and Appeal Board that it had the same obligation to provide a thorough explanation of its reasoning when it issues Final Written Decisions.  "When the Board determines that modifications and combinations of the prior art render a claimed invention obvious, the Board must fully explain why a person of ordinary skill in the art would find such changes obvious."  Because the Board did not do so in this case, the decision was vacated and remanded.     

    The case stems from an inter partes review of U.S. Patent No. 7,990,018, owned by Cutsforth, Inc.  The technology at issue involved brush holder assemblies that allowed a current to pass from a stationary device to a moving contact.  The stationary device could be a brush made of conductive material, with a brush holder that would allow a continuous contact with the moving conductive surface to generate an electrical current.  The claimed assembly allowed for easier removal, allowing brush replacement during operation.  MotivePower filed five IPR petitions directed to the '018 patent and related patents, all of which were instituted.  Ultimately, no challenged claim survived (either through voluntary cancellation or a finding of unpatentability by the Board).  Three of the five decisions were appealed, and were consolidated for purposes of oral argument.  This opinion, however, only appears to address the IPR directed to the '018 patent.

    The challenged claims of the '018 patent were found to be obvious in view of three prior art references, Bissett, Ohmstedt, and Kartman.  The Board began its analysis of independent claim 1 by reiterating the assertions of the petitioner:

    Concerning independent claim 1, Petitioner contends that Bissett discloses a brush holder component (brush assembly 12) adapted for removably mounting to the mounting block (dovetails 18) by providing a channel for receiving a portion of the mounting block (dovetails 18). Pet. 16 (citing Ex. 1005, 1:61–2:1, Figs. 3–4). Furthermore, Petitioner argues that it would have been obvious to adapt the brush holder (brush assembly 12) of Bissett to include the brush catch of Ohmstedt, whereby divergent portion 23 of Ohmstedt would extend downward from the Bissett channel such that teeth 25 of Ohmstedt engage the Bissett brush 24. Pet. 10 (citing Ex. 1003, 1:14–18, 28–50; Ex. 1005, Fig. 4). Accordingly, Petitioner argues that the brush catch of Ohmstedt (divergent portion 23 and teeth 25) has a first position preventing sliding movement of a brush and a second position permitting sliding movement of a brush. Pet. 16 (Ex. 1003, 2:5–49, 3:8–12, Figs. 1, 2). Additionally, Petitioner argues that it would have been obvious to include the Ohmstedt brush release (ramps 59) in a position to engage the brush catch below the mounting structure (dovetails 18). Pet. 10–11, 17 (citing Ex. 1003, 2:15–17, 39–43, Fig. 2). The Petitioner also argues that it would have been obvious to adapt the mounting block of Bissett (dovetails 18) with the mounting block of Kartman. Pet. 11–12 (citing Ex. 1004, 4:19–22 and Ex. 1005, 1:63–64). More particularly, Petitioner proposes that the "T" shaped channel in Bissett may be modified to incorporate the elongated mounting block structure of Kartman (detachable connecting means 42), which also is configured to slidably engage a "T" shaped channel. Pet. 12–13 (citing Ex. 1004, 4:19–22, Fig. 3; Ex. 1005, 1:63–64, Fig. 4).

    IPR2013-00274, Final Written Decision at pp. 19-20.  After the Board explained how the patent owner responded, it rejected these arguments stating that it was "not persuaded by Patent Owner's argument[s]" or assertions.  But nowhere in the decision did the Board explain its reasoning why the claims were obviousness in the first place, nor did it explicitly adopt the Patent Owner's allegations as its own.        

    For claims 5 and 8, which ultimately depended from claim 1, the additional elements of a spring and a movable portion were recited.  The Board found that the prior art also recited such features, even if not necessarily on the mounting block.  Instead, the Board explained that the specific placement of the claimed spring and movable portion are matters of "design choice."  No other reasons were provided by the Board as to why these modifications were obvious, or why a person of ordinary skill in the art would have been motivated to make them.

    The Federal Circuit held, in much the same was as it did earlier in In re Sang-Su Lee, that the reasoning for the rejection/cancelation must be articulated.  Otherwise, the patent owner would be at a loss as to how to mount a competent appeal, and the Federal Circuit would be unable to conduct a meaningful review.  Especially for obviousness determinations, "the Board must explain why a person of ordinary skill in the art would modify the prior art references to create the claimed invention."  In the present case, the Court found that the Board merely restated the arguments of the petitioner without accepting them for itself.  The decision therefore read as though the Board assumed the combination was obvious, and that the Patent Owner had failed to establish the claims were non-obvious.  This, of course, essentially amounts to a burden shift, requiring the Patent Owner to show why it was entitled to a patent rather than requiring than requiring the petitioner to establish by a preponderance of the evidence why the claims were obvious.

    With regard to the "design choice" argument posited by the Board, the Federal Circuit explained that even if the particular placement of the element was a design choice, it did not necessarily render the placement obvious.  Instead, there must be some reason why a person of skill in the art would have made the particular design choice.  The Board did not provide this reason.

    This case might appear as a win for patent owners, and indeed the Board will certainly be more careful in articulating its reasoning in future final written decisions.  However, on remand, it is conceivable that the Board could merely modify the final written decision to add that it adopted all of the reasoning of the petitioner as its own.  And, realistically going forward, if the Board thinks that a particular claim is obvious, it will likely be able to provide some reasoning sufficient to satisfy the holding in this case.  Therefore, even if at first blush this case seems to be a panacea for patent owners, it is unlikely that it will have the same impact for practitioners that the In re Sang-Su Lee case did back in 2002.

    Cutsforth Inc. v. MotivePower, Inc. (Fed. Cir. 2016)
    Nonprecedential disposition
    Panel: Chief Judge prost and Circuit Judges Clevenger and Moore
    Opinion by Circuit Judge Clevenger

  •         By Sherri Oslick —

    Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

    Purdue Pharma L.P. et al. v. Amneal Pharmaceuticals LLC
    1:15-cv-00831; filed September 17, 2015 in the District Court of Delaware

    • Plaintiffs:  Purdue Pharma L.P.; P.F. Laboratories Inc.; Purdue Pharmaceuticals L.P.
    • Defendant:  Amneal Pharmaceuticals LLC

    Infringement of U.S. Patent Nos. 9,060,976 ("Pharmaceutical Formulation Containing Gelling Agent" issued June 23, 2015) and 9,034,376 (same title, issued May 19, 2015) following a Paragraph IV certification as part of Amneal's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain).  View the complaint here.


    Horizon Pharma Ireland Ltd. et al. v. Lupin Ltd. et al.
    1:15-cv-06935; filed September 17, 2015 in the District Court of New Jersey

    • Plaintiffs: Horizon Pharma Ireland Ltd.; HZNP Limited; Horizon Pharma USA, Inc.
    • Defendants: Lupin Ltd.; Lupin Pharmaceuticals, Inc.

    Horizon Pharma Ireland Ltd. et al. v. Actavis Laboratories UT, Inc. et al.
    1:15-cv-06989; filed September 17, 2015 in the District Court of New Jersey

    • Plaintiffs: Horizon Pharma Ireland Ltd.; HZNP Limited; Horizon Pharma USA, Inc.
    • Defendants: Actavis Laboratories UT, Inc.; Actavis, Inc.; Allergan PLC

    Horizon Pharma Ireland Ltd. et al. v. IGI Laboratories, Inc.
    1:15-cv-06991; filed September 17, 2015 in the District Court of New Jersey

    • Plaintiffs: Horizon Pharma Ireland Ltd.; HZNP Limited; Horizon Pharma USA, Inc.
    • Defendant: IGI Laboratories, Inc.

    Horizon Pharma Ireland Ltd. et al. v. Amneal Pharmaceuticals LLC
    1:15-cv-06990; filed September 17, 2015 in the District Court of New Jersey

    • Plaintiffs: Horizon Pharma Ireland Ltd.; HZNP Limited; Horizon Pharma USA, Inc.
    • Defendant: Amneal Pharmaceuticals LLC

    The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 9,132,110 ("Treatment of Pain with Topical Diclofenac," issued September 15, 2015) in conjunction with defendants' filing of an ANDA to manufacture a generic version of Horizon's Pennsaid® (diclofenac sodium topical solution, used for the treatment of signs and symptoms of osteoarthritis of the knee(s)).  View the Lupin complaint here.


    Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc. et al.
    2:15-cv-06934; filed September 17, 2015 in the District Court of New Jersey

    • Plaintiff:  Impax Laboratories, Inc.
    • Defendants:  Actavis Laboratories FL, Inc.; Actavis Pharma Inc.

    Infringement of U.S. Patent Nos. 7,094,427 ("Combination Immediate Release Controlled Release Levodopa/Carbidopa Dosage Forms," issued August 22, 2006), 8,377,474 ("Controlled Release Formulations of Levodopa and Uses Thereof," issued February 19, 2013), 8,454,998 (same title, issued June 4, 2013), 8,557,283 (same title, issued October 15, 2013), 9,089,607 (same title, issued July 28, 2015), and 9,089,608 (same title, issued July 28, 2015) following a Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Impax's Rytary® (levodopa and carbidopa, used to treat Parkinson's disease).  View the complaint here.


    Gilead Sciences, Inc. et al. v. Lupin Pharmaceuticals, Inc. et al.
    1:15-cv-02793; filed September 16, 2016 in the District Court of Maryland

    • Plaintiffs:  Gilead Sciences, Inc.; Hoffmann-LaRoche Inc.; F. Hoffmann-LaRoche LTD; Genentech, Inc.
    • Defendants:  Lupin Pharmaceuticals, Inc.; Lupin Atlantis Holdings S.A.; Lupin Ltd.

    Infringement of U.S. Patent No. 5,763,483 ("Carbocyclic Compounds," issued June 9, 1998) following a Paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of Genentech's Tamiflu® (oseltamivir phosphate, used to treat uncomplicated acute illness due to influenza infection in patients one year or older who have been symptomatic for no more than two days and for the prophylaxis of influenza in patients one year or older).  View the complaint here.


    Otsuka Pharmaceutical Co. Ltd. v. Hetero USA Inc. et al.
    1:15-cv-00822; filed September 15, 2015 in the District Court of Delaware

    • Plaintiff:  Otsuka Pharmaceutical Co. Ltd.
    • Defendants:  Hetero USA Inc.; Hetero Labs Ltd.; Hetero Labs Ltd. Unit V

    Infringement of U.S. Patent No. 5,753,677 ("Benzoheterocyclic Compounds," issued May 19, 1998) following a Paragraph IV certification as part of Hetero's filing of an ANDA to manufacture a generic version of Otsuka's Samsca® (tolvaptan, used to treat hyponatremia).  View the complaint here.  [NB: This case has been dismissed.]


    Acorda Therapeutics Inc. v. Par Pharmaceutical Inc.
    1:15-cv-00824; filed September 15, 2015 in the District Court of Delaware

    Infringement of U.S. Patent Nos. 8,007,826 ("Sustained Release Aminopyridine Composition," issued August 30, 2011), 8,354,437 ("Method of Using Sustained Release Aminopyridine Compositions," issued January 15, 2013), 8,440,703 (same title, issued May 14, 2013), and 8,663,685 ("Sustained Release Aminopyridine Composition," issued March 4, 2014) following a Paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of Acorda's Ampyra® (dalfampridine extended release, used to improve walking in patients with multiple sclerosis).  View the complaint here.


    Allergan, Inc. v. InnoPharma, Inc. et al.
    1:15-cv-00815; filed September 14, 2015 in the District Court of Delaware

    • Plaintiff:  Allergan, Inc.
    • Defendants:  InnoPharma, Inc.; Pfizer Inc.

    Infringement of U.S Patent Nos. 8,629,111 ("Methods of Providing Therapeutic Effects Using Cyclosporine Components," issued January 14, 2014), 8,633,162 (same title, issued January 21, 2014), 8,642,556 (same title, issued February 4, 2014), 8,648,048 (same title, issued February 11, 2014), and 8,685,930 (same title, issued April 1, 2014) following a Paragraph IV certification as part of InnoPharma's filing of an ANDA to manufacture a generic version of Allergan's Restasis® (cyclosporine ophthalmic emulsion, 0.05%, used to treat dry eye).  View the complaint here.  [NB: This case has been dismissed.]

  • By Kevin E. Noonan —

    CRISPR (an acronym for Clustered Regularly lnterspaced Short Palindromic Repeats), which is part of a system for altering chromosomal sequences in situ in a cell in combination with a bacterially derived protein called Cas9, has been hailed as the "Breakthrough of the Year" for 2015, and rightfully so.  Just as the discovery of bacterial restriction enzymes by Cohen and Boyer in 1972 provided the ability to dissect DNA at specific sites in the DNA sequence, CRISPR provides a mechanism for inserting or deleting specific DNA sequences using CRISPR-associate targeting RNAs and the Cas9 RNA-guided DNA endonuclease enzyme.  It provides for the first time the type of specificity for altering DNA that the polymerase chain reaction (PCR) provided a generation ago for amplifying specific DNA, as illustrated by this schematic:

    Figure
    Given the commercial potential of this method, patenting is an obvious concern and, as it turns out, more than one group of inventors has filed patent applications on the reagents, methods, and cells produced or used to produce CRISPR modifications.  Because these applications were filed prior to March 16, 2013, the inventor(s) who first invented this invention have the right to patent it, and disputes regarding who was the first to invent are resolved using a procedure called an interference.

    In this case, on January 11, 2016, the U.S. Patent and Trademark declared Interference No. 106,048 under the provisions of 37 C.F.R. § 41.203(b), naming Feng Zhang and his colleagues, the named inventor of the Broad Institute/MIT's patents, as the Junior Party, and Jennifer Doudna and her colleagues at UC/Berkeley as Senior Party (see Declaration).  These designations stem from which party was the first to file a patent application and are important, because (without evidence to the contrary) the PTO considers the Senior Party to be the presumptive inventor (and thus the burden to establish prior right based on earlier invention is borne by the Junior Party).

    Paradoxically, the Broad Institute/MIT inventors have obtained a number of patents even though the Berkeley inventors have the earliest filing date and no issued patents (which is important because an interference cannot resolve the dispute between patents granted on the same invention).  This is because the Broad availed itself of priority examination ("fast track") provisions of the law.  In fact, the Broad attempted to provoke an interference with the Berkeley patents, albeit involving a fewer number of patents and claims than are involved in this interference.  The Broad patents (and their involved claims, which constitute all of the granted claims of all of the Broad patents) are:

    • Patent 8,697,359 – claims 1-20
    • Patent 8,771,945 – claims 1-29
    • Patent 8,795,965 – claims 1-30
    • Patent 8,865,406 – claims 1-30
    • Patent 8,871,445 – claims 1-30
    • Patent 8,889,356 – claims 1-30
    • Patent 8,895,308 – claims 1-30
    • Patent 8,906,616 – claims 1-30
    • Patent 8,932,814 – claims 1-30
    • Patent 8,945,839 – claims 1-28
    • Patent 8,993,233 – claims 1-43
    • Patent 8,999,641 – claims 1-28*,

    while only one pending application from the Berkeley group is involved in the interference:

    • US 2014-0068797 A1 – claims 165, 200, 202-218, 220-222 and 224-247.

    Representative claims of each party are as follows:

    The Broad/MIT:

    1.    An engineered, non-naturally occurring CRISPR-Cas system comprising one or more vectors comprising:
        a) a first regulatory element operable in a eukaryotic cell operably linked to at least one nucleotide sequence encoding a CRISPR-Cas system guide RNA that hybridizes with a target sequence of a DNA molecule in a eukaryotic cell that contains the DNA molecule, wherein the DNA molecule encodes and the eukaryotic cell expresses at least one gene product, and
        b) a second regulatory element operable in a eukaryotic cell operably linked to a nucleotide sequence encoding a Type-II Cas9 protein,
        wherein components (a) and (b) are located on same or different vectors of the system, whereby the guide RNA targets and hybridizes with the target sequence and the Cas9 protein cleaves the DNA molecule, whereby expression of the at least one gene product is altered; and, wherein the Cas9 protein and the guide RNA do not naturally occur together.

    5.    A method of altering expression of at least one gene product comprising introducing into a eukaryotic cell containing and expressing a DNA molecule having a target sequence and encoding the gene product an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)–CRISPR associated (Cas) (CRISPR-Cas) system comprising one or more vectors comprising:
        a) a first regulatory element operable in a eukaryotic cell operably linked to at least one nucleotide sequence encoding a CRISPR-Cas system guide RNA that hybridizes with the target sequence, and
        b) a second regulatory element operable in a eukaryotic cell operably linked to a nucleotide sequence encoding a Type-II Cas9 protein,
        wherein components (a) and (b) are located on same or different vectors of the system, whereby the guide RNA targets the target sequence and the Cas9 protein cleaves the DNA molecule, whereby expression of the at least one gene product is altered; and, wherein the Cas9 protein and the guide RNA do not naturally occur together.

    6.    A CRISPR-Cas system-mediated genome editing method comprising introducing into a eukaryotic cell containing and expressing a DNA molecule having a target sequence and encoding at least one gene product an engineered, non-naturally occurring CRISPR-Cas system comprising one or more vectors comprising:
        a) a first regulatory element operable in a eukaryotic cell operably linked to at least one nucleotide sequence encoding a CRISPR-Cas system guide RNA that hybridizes with the target sequence, and
        b) a second regulatory element operable in a eukaryotic cell operably linked to a nucleotide sequence encoding a Type-II Cas9 protein,
        wherein components (a) and (b) are located on same or different vectors of the system, whereby expression of the at least one gene product is altered through the CRISPR-Cas system acting as to the DNA molecule comprising the guide RNA directing sequence-specific binding of the CRISPR-Cas system, whereby there is genome editing; and, wherein the Cas9 protein and the guide RNA do not naturally occur together.

    Berkeley:

    165.    A method of cleaving a nucleic acid comprising contacting a target DNA molecule having a target sequence with an engineered and/or non-naturally-occurring Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising
        a) a Cas9 protein; and
        b) a single molecule DNA-targeting RNA comprising
            i) a targeter-RNA that hybridizes with the target sequence, and
            ii) an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA duplex of a protein-binding segment,
        wherein the activator-RNA and the targeter-RNA are covalently linked to one another with intervening nucleotides,
        wherein the single molecule DNA-targeting RNA forms a complex with the Cas9protein,
        whereby the single molecule DNA-targeting RNA targets the target sequence, and the Cas9 protein cleaves the target DNA molecule.

    203.    An engineered and/or non-naturally occurring Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising
        a) a Cas9 protein, or a nucleic acid comprising a nucleotide sequence encoding said Cas9 protein; and
        b) a single molecule DNA-targeting RNA, or a nucleic acid comprising a nucleotide sequence encoding said single molecule DNA-targeting RNA;
        wherein the single molecule DNA-targeting RNA comprises:
        i) a targeter-RNA that is capable of hybridizing with a target sequence in a target DNA molecule, and
        ii) an activator-RNA that is capable of hybridizing with the targeter-RNA to form a double-stranded RNA duplex of a protein-binding segment,
        wherein the activator-RNA and the targeter-RNA are covalently linked to one another with intervening nucleotides; and
        wherein the single molecule DNA-targeting RNA is capable of forming a complex with the Cas9 protein, thereby targeting the Cas9 protein to the target DNA molecule,
        whereby said system is capable of cleaving or editing the target DNA molecule or modulating transcription of at least one gene encoded by the target DNA molecule.

    224.    A Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising:
        a Cas9 protein; and
        a single molecule DNA-targeting RNA, or a nucleic acid comprising a nucleotide sequence encoding said single molecule DNA-targeting RNA,
        wherein the single molecule DNA-targeting RNA comprises:
            i) a targeter-RNA that is capable of hybridizing with a target sequence in a target DNA molecule, and
            ii) an activator-RNA that is capable of hybridizing with the targeter-RNA to form a double-stranded duplex of a protein-binding segment,
        wherein i) and ii) are arranged in a 5' to 3' orientation and are covalently linked to one another with intervening nucleotides;
        wherein the single molecule DNA-targeting RNA is capable of forming a complex with the Cas9 protein and hybridization of the targeter-RNA to the target sequence is capable of targeting the Cas9 protein to the target DNA molecule, and
        wherein the single molecule DNA-targeting RNA comprises one or more sequence modifications compared to a sequence of a corresponding wild type tracrRNA and/or crRNA.

    In an interference, the PTO establishes one or more "counts," which is a phantom claim that encompasses the interfering subject matter.  The parties provide evidence of conception of at least one embodiment falling within the scope of the count and reduction to practice (actual or constructive, i.e., by filing a patent application having an enabling disclosure of said one embodiment).  While there are several complicated scenarios that can arise in an interference, generally a party that conceived first and reduced to practice first, and did not abandon, suppress or conceal the invention, will prevail.  The sole Count in the CRISPR interference reads as follows:

    Count 1

    A method, in a eukaryotic cell, of cleaving or editing a target DNA molecule or modulating transcription of at least one gene encoded thereon, the method comprising:
        contacting, in a eukaryotic cell, a target DNA molecule having a target sequence with an engineered and/or non-naturally-occurring Type II Clustered Regularly lnterspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising:
        a) a DNA-targeting RNA comprising
            i) a targeter-RNA or guide sequence that hybridizes with the target sequence, and
            ii) an activator-RNA or tracr sequence that hybridizes with the targeter-RNA to form a double-stranded RNA duplex of a protein-binding segment, and
        b) a Cas9 protein,
        wherein the DNA-targeting RNA forms a complex with the Cas9 protein, thereby targeting the Cas9 protein to the target DNA molecule, whereby said target DNA molecule is cleaved or edited or transcription of at least one gene encoded by the target DNA molecule is modulated.

    The interference will proceed in two stages.  The first stage involves the parties presenting motions that can modify the count, have certain claims declared outside the scope of the count (or vice versa), and ask for a finding that the claims are invalid under any of the provisions of the patent statute.  If these motions are not decided in a way that would disqualify one or both parties, then the interference will move to a second stage, where the Junior Party (The Broad) will present its proofs of conception and reduction to practice and the Senior Party will be permitted to oppose.  The Senior Party is under no obligation to present proofs earlier than its earliest filing date unless the Junior Party evinces evidence of (at least) earlier conception.  In practice, the parties can both be expected to submit their evidence.

    The parties can also settle the inference privately, with the losing party filing a Concession of Priority and the prevailing party (usually) granting a license to the loser; such settlement agreements are kept confidential but must be filed.  Otherwise, everything else in an interference is public information and can be found under the Patent Trial and Appeal Board (PTAB) on the Office's PAIR website.  Office rules mandate the times for these two stages and an interference is usually concluded with a decision (if not earlier settled) within 36 months of the Declaration.

    * The Broad/MIT also have several pending applications, including US 2014-0186919 A1; US 2014-0179770 A1; US 2014-0242664 A1; US 2014-0310830 A1; US 2014-0189896 A1; US 2014-0242699 A1; US 2014-0357530 A1; US 2015-0020223 A1; and US 2015-0079681 A1.  Should allowable claims be presented in any of these applications such claims may become involved in this interference.

  • By Donald Zuhn —

    House of Representatives SealIn a letter sent earlier this month to Secretary Sylvia Mathews Burwell of the U.S. Department of Health & Human Services and Director Francis S. Collins of the National Institutes of Health, fifty members of the U.S. House of Representatives urged Secretary Burwell and Director Collins to use their existing statutory authority to respond to the soaring cost of pharmaceuticals.

    The letter begins by noting that the Bayh-Dole Act authorizes federal agencies that fund private research to retain certain rights in patented inventions, including march-in rights under 35 U.S.C. § 203(a)(2) that can be used when the benefits of patented products are not available to the public on reasonable terms.  The letter then notes that the NIH "has not previously offered official guidance regarding the situations in which march-in rights would apply," asserts that "reasonable guidelines can discourage drug price gouging," and "urge[s] NIH to issue guidelines to accomplish this goal."  While acknowledging that the NIH has "appropriately referred to march-in rights as an 'extraordinary remedy'," the Representatives argue that "too many families and providers are facing an extraordinary challenge from unreasonably priced pharmaceuticals."

    The Representatives express confidence in the NIH's ability to craft reasonable guidance that would "address price gouging while ensuring that march-in rights are exercised with transparency and fairness."  The signatories also suggest that because such rights "would only be used when wrongdoing occurs, innovation should not be threatened," and argue that "[e]stablishing strong guidelines [would] protect[] consumers while reducing the need for having to actually exercise 'march-in' rights."

    The Representatives also take the NIH to task for declining to exercise march-in rights in the past while suggesting that controlling drug costs is a legislative duty.  Although the letter does not dispute the accuracy of such a suggestion, the Representatives counter that "Congress legislated long ago on a bipartisan basis in delegating authority to federal agencies such as NIH the responsibility to address one aspect of this problem," and declare that "[w]e call upon you to do that job."

    The Representatives also note that despite some estimates that a quarter of all priority-reviewed drugs might be impacted by the NIH exercising its march-in rights, "we believe that just the announcement of reasonable guidelines in response to price gouging would positively influence pricing across the pharmaceutical industry."  The Representatives conclude the letter by requesting the NIH's "prompt response in bringing relief for struggling patients and families."

  • By Donald Zuhn –-

    USPTO SealFor the second time in a little more than a month, the U.S. Patent and Trademark Office has experienced an unexpected closing.  Last month, the closing resulted from a major power outage at USPTO headquarters in Alexandria, VA that significantly damaged the Office's electronic systems and required the shutdown of its online and IT systems.  During the earlier shutdown, the Office considered each day from December 22-24 to be a "Federal holiday within the District of Columbia" under 35 U.S.C. § 21 and 37 C.F.R. §§ 1.6, 1.7, 1.9, 2.2(d), 2.195, and 2.196 (see "Major Power Outage Causes Shutdown of USPTO Online and IT Systems — USPTO to Consider December 22-24 to be 'Federal Holidays'").

    Following last weekend's winter storm, which dumped nearly 18 inches of snow on Washington, DC, and between 18 and 24 inches (or more) of snow in the immediate D.C. Metro area, Federal agencies in the Washington, DC area, including the USPTO, were closed on Monday, January 25, and Tuesday, January 26.  The USPTO posted notices on the Office's Operating Status webpage that as a result of the official closing of Federal Government offices in the Washington, D.C. metropolitan area on January 25-26, the Office would consider each day a "Federal holiday within the District of Columbia" under 35 U.S.C. § 21 and 37 C.F.R. §§ 1.6, 1.7, 1.9, 2.2(d), 2.195, and 2.196.  As a result, the Office will consider any action or fee due on January 25-26 as timely if the action is taken, or the fee is paid, on the next succeeding business day on which the USPTO is open (see 37 C.F.R. §§ 1.7(a) and 2.196).  According to the Office, actions that are taken or fees that are paid on the next succeeding business day on which the USPTO is open will be considered timely for the purposes of, for example, 15 U.S.C. §§ 1051(b), 1058, 1059, 1062(b), 1063, 1064, and 1126(d), or 35 U.S.C. §§ 119, 120, 133, and 151.

    Washington - Capitol & Snow #1With regard to the Office's operating status on Wednesday, the U.S. Office of Personnel Management (OPM) website has posted a notice that Federal agencies in the Washington, DC area will be open on January 27 — albeit under three hours delayed arrival status, in which Federal employees should plan to arrive for work no more than three hours later than they would be expected to arrive.  Federal employees will also be given the option for unscheduled leave or unscheduled telework.  For weather-related closings in the Washington, DC area, the USPTO follows OPM guidance.  Patent Docs will provide an update as soon as the USPTO determines its operating status for Wednesday.

    According to the WUSA website, Winter Storm Jonas tied for fourth on the Washington, DC list of top 10 snowfalls:

    1 – 28.0" (January 27-29, 1922)
    2 – 20.0" (February 12-14, 1899)
    3 – 18.7" (February 18-19, 1979)
    4 – 17.8" (January 22-23, 2016)
    4 – 17.8" (February 5-6, 2010)
    6 – 17.3" (January 7-9, 1996)
    7 – 16.6" (February 10-11, 1983)
    8 – 16.4" (December 18-19, 2009)
    9 – 16.4" (February 16-18, 2003)
    10 – 14.4" (February 15-16, 1958)

    Interestingly enough, the February 5-6, 2010 storm, which also dropped 17.8 inches of snow on the city, led to USPTO closings on Monday, February 8 through Thursday, February 11 (see "USPTO Closed on Monday and Tuesday, February 8-9, 2010"; "Patent Office Remains Closed for February 10, 2010"; and "USPTO Remains Closed For February 11, 2010").

  • By Michael Borella —

    District Court for the Eastern District of TexasVoxathon sued Alpine, and a number of defendants that manufacture automobiles, for infringement of U.S. Patent No. 6,442,261.  According to the Court, the patent "relates to computer-implemented systems and methods for transferring information efficiently."  Specifically, claim 1 recites:

    A method for recovering calls using an attendant telephone set having a predetermined number of call appearance buttons comprising:
        receiving a plurality of incoming telephone calls from calling parties;
        identifying a telephone number of the calling party of each incoming telephone call;
        assigning each incoming telephone call to a next available call appearance button of said predetermined number of call appearance buttons;
        storing the identified telephone number associated with each incoming telephone call in a memory device; and
        automatically redialing, in response to the attendant's  selection of one of the call appearance buttons, the stored telephone number of the calling party of the incoming call assigned to the selected call appearance button.

    The defendants filed multiple 12(b)(6) motions to dismiss the case on the grounds that the claims of the '261 patent lack subject matter eligibility under 35 U.S.C. § 101.  The Court found that there were no material factual disputes that prevented it from evaluating these motions on the pleadings.  Despite Voxathon arguing that the defendants had misconstrued or disregarded several claim terms, the Court stated that construction of these terms would not change the substantive § 101 analysis.  Citing to the precedential Federal Circuit case of Bancorp Servs., L.L.C. v. Sun Life. Assur. Co. of Canada, the Court stated that it was not required to wait until after claim construction to make a § 101 determination.

    That out of the way, the Court reviewed the two-prong test for patent-eligibility under § 101 set forth in Alice Corp. v. CLS Bank Int'l.  First, one must determine whether the claim at hand is directed to a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then one must further determine whether any element, or combination of elements, in the claim is sufficient to ensure that the claim amounts to something more than the judicial exception.  Notably, generic computer implementation of an otherwise abstract process does not qualify as "something more."

    Applying the first prong, the Court characterized the claim as "directed to the abstract idea of responding to a sender of a message."  Despite explicit recitation of "a telephone set" and "call appearance buttons," the Court made an analogy between the claimed invention and a manual procedure that could be carried out by a human.  Particularly, the Court wrote that "[w]hether a message is received through a telephone or a letter, the steps of receiving a message, identifying the sender of the message, remembering the address or phone number of the sender of the message, and responding to the sender of a message remain the same."

    Voxathon argued that the claims disclosed an improved telephone set that solved problems in the prior art related to telephone calls going unanswered.  The Court rejected this notion, stating that any such new device "merely performs the abstract idea of responding to the sender of a message."  Looking to the claims found ineligible in Planet Bingo, LLC v. VKGS LLC and Content Extraction and Transmission LLC v. Wells Fargo Bank, National Ass'n, the Court concluded that the '261 patent similarly included steps of "1) collecting data, 2) recognizing certain data within the collected data set, and 3) storing that recognized data in a memory," and that the recalling step did not make a significant difference.

    Turning to the second prong, Voxathon used an expert declaration in an attempt to establish that the claim contains "several material, non-generic limitations."  The Court, however, rejected the declaration as being "inadequate" without explaining why.  (Apparently, this declaration did not raise a material issue of fact that prevented the Court from ruling on the 12(b)(6) motion.)  Instead, the Court stated that "the '261 patent simply automates an abstract idea — responding to the sender of a message — albeit through the use of a 'telephone set,'" and that "[a] generic computer can perform the same conventional and routine steps as the 'telephone set.'"

    Voxathon further argued that the claimed invention "eliminates errors associated with the process of receiving and redialing a phone number."  But the Court found this notion unavailing, because even "[t]hough a computer may be more efficient or less error-prone than a human, mere automation through a generic computer is not enough to render a patent eligible under § 101."  Finally, Voxathon noted that the claim's preemption is "narrow and not absolute."  Once again, the Court was unconvinced, and noted that the absence of compete preemption does not demonstrate patent-eligibility, and that the claim is effectively a monopoly over the aforementioned abstract idea.

    Consequently, the '261 patent was held to be invalid under § 101, and the case was dismissed.

    This is yet another example that tracks a familiar trend in § 101 jurisprudence: (1) a claim is viewed at a 10,000 foot level to remove from it all devices and machines, (2) this gist of the claim is declared abstract, and (3) when the devices and machines are examined separately from this gist of the claim, they are determined to be no more than routine and conventional, adding no patentable weight.  Following such a formula, virtually any software or business method claim can be rendered invalid.

    And therein lays the fundamental problem with the Alice test — its subjectivity.  While many claims that fail to meet the requirements of § 101 are more clearly abstract than claim 1 of the '261 patent, a reasonable application of the test to this claim — one that considered the claim as a whole or involved defining claim terms — might have come to the opposite conclusion.

  • Financial Services Patent Claims Invalid

    By Joseph Herndon —

    Federal Circuit SealOn January 20, 2016, the Federal Circuit issued an opinion in the case captioned Mortgage Grader, Inc. v. First Choice Loan Services Inc., NYLX, Inc.  This case involves patent claims directed to systems and methods for assisting borrowers to obtain loans.  Mortgage Grader appealed the District Court's finding that the asserted claims are patent-ineligible on summary judgment.  Here, the Federal Circuit affirmed that finding.  This decision by the Federal Circuit stays in line with the Alice decision and the Federal Circuit decisions following Alice, and provides a large roadblock to any patent owner looking to assert any type of financial or economic practice-based patent claims.

    Turning to the patents and substance of the patent-ineligibility challenge under § 101, the patents-in-suit, U.S. Patent Nos. 7,366,694 and 7,680,728, relate to financial transactions including a method for a borrower to evaluate and/or obtain financing, e.g., a loan. Claim 1 of the ‘694 patent is representative and reproduced here:

    1.  A computer-implemented system for enabling borrowers to anonymously shop for loan packages offered by a plurality of lenders, the system comprising:
        a database that stores loan package data specifying loan packages for home loans offered by the lenders, the loan package data specifying, for each of the loan packages, at least a loan type, an interest rate, and a required borrower credit grading; and
        a computer system that provides:
            a first interface that allows the lenders to securely upload at least some of the loan package data for their respective loan packages to the database over a computer network; and
            a second interface that prompts a borrower to enter personal loan evaluation information, and invokes, on a computer, a borrower grading module which uses at least the entered personal loan evaluation information to calculate a credit grading for the borrower, said credit grading being distinct from a credit score of the borrower, and being based on underwriting criteria used by at least some of said lenders;
            wherein the second interface provides functionality for the borrower to search the database to identify a set of loan packages for which the borrower qualifies based on the credit grading, and to compare the loan packages within the set, including loan type and interest rate, while remaining anonymous to each of the lenders and without having to post a request to any of the lenders, said second interface configured to display to the borrower an indication of a total cost of each loan package in the set, said total cost including costs of closing services not provided by corresponding lenders.

    The District Court concluded that all of the asserted claims are directed to the abstract idea of "anonymous loan shopping" and that they include no "inventive concept."

    On Appeal, the Federal Circuit followed the two-step framework for distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.  First, the court determines if the claims at issue are directed to a patent-ineligible concept.  If not, the inquiry ends, as the claims are patent-eligible.  But if so, the next step is to look for an "inventive concept" — i.e., an element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself.

    1.  Are the claims directed to a patent-ineligible concept?

    Regarding step 1, the Federal Circuit agreed with the District Court that the asserted claims are directed to the abstract idea of "anonymous loan shopping."

    The claim limitations recite nothing more than the collection of information to generate a "credit grading" and to facilitate anonymous loan shopping.  As the District Court explained, the claims specify that "the borrower is anonymous to the lender until the borrower has been informed of the cost of the loan based on the borrower's credit grading, and the borrower then chooses to expose its identity to a lender."

    The Federal Circuit simplified the series of steps covered by the asserted claims to be a borrower applies for a loan, a third party calculates the borrower's credit grading, lenders provide loan pricing information to the third party based on the borrower's credit grading, and only thereafter (at the election of the borrower) the borrower discloses its identity to a lender.  These simplified steps were found to be capable of being performed by humans without a computer.  This reasoning further supported the Federal Circuit's finding that the claims are directed to an "abstract idea".

    2.  Do the claims include an "inventive concept"?

    The Federal Circuit found that no inventive concept was recited in the claims that could save the claims from being found invalid under § 101.  Instead, the claims add only generic computer components such as an "interface," "network," and "database."

    It is well known now that generic computer components do not satisfy the inventive concept requirement.

    The Federal Circuit noted that the two common reasons found in prior cases for supporting "inventive concepts" were lacking in the instant case.  First, because nothing in the asserted claims purports to improve the functioning of the computer itself or effect an improvement in any other technology or technical field, there can be no inventive concept due to recitation of the generic computer components.  Second, the Federal Circuit further noted that the claims also do not solve any problem unique to the Internet of computer technical field.  For completeness, the Federal Circuit noted that the claims further are not adequately tied to "a particular machine or apparatus", which could have provided supported for patentability under Bilski.

    Thus, because the asserted claims are directed to an abstract idea and nothing in the claims adds an inventive concept, the claims are not patent-eligible under § 101.

    3.  Do §101 inquiries require resolution of underlying factual issues?

    Mortgage Grader argued that the District Court improperly resolved material factual disputes in connection with granting First Choice Loan's summary judgment motion of patent ineligibility.  The Federal Circuit disagreed, and noted that the mere existence of some alleged factual dispute between the parties will not defeat an otherwise properly supported motion for summary judgment.

    The § 101 inquiry may contain underlying factual issues, but here, the Federal Circuit performed the § 101 analysis without resolving fact issues.  Since the issues were not considered to be directed to a material fact, summary judgment was still appropriate.

    The Federal Circuit noted that the parties submitted expert declarations, and the District Court acknowledged these materials were in the record.  But the District Court did not rely on them in its § 101 analysis.  Instead, in making its patent-eligibility determination, the District Court looked only to the claims and specifications of the patents-in-suit.

    The Federal Circuit noted that the mere existence in the record of dueling expert testimony does not necessarily raise a genuine issue of material fact.  However, the Federal Circuit did review the expert opinions, and disposed of them in turn.

    For instance, the Federal Circuit noted that First Choice Loan's experts simply provided non-material historical information about how people obtained mortgages in the period before the Internet, and this was considered by the Federal Circuit to add little if anything to the '694 patent's specification, which observed that "[t]here are newspaper or Internet referral sites which publish interest rates for one or more lenders."

    Further, Mortgage Grader's expert stated, neither of First Choice Loan's experts "reference[d] the asserted claims, but instead merely explain[ed] the existence of mortgage rate tables published in newspapers during the 1980s and 1990s."  Mortgage Grader's expert opined that the patents-in-suit solved the problem of information asymmetry between borrowers and lenders, which had previously permitted lenders to "steer" borrowers to predatory loans.  But that assertion about problem solving does not by its terms identify claimed process steps.

    In any event, the claims expressly encompass so-called "independent" third-parties who, in addition to determining a borrower's credit grading, may be "full time employee[s] of an entity providing the desired financial services" and may "receive[] a percentage commission from an affiliated company based on the loans funded through the program."  Plainly speaking, the Federal Circuit stated, conflicts-of-interest and predatory lending are still possible when practicing the claims, and thus, the Federal Circuit did not believe Mortgage Grader's expert opinions had any effect on the patent ineligibility analysis.

    Mortgage Grader's expert also provided an opinion that the patents-in-suit require use of a computer.  But, the Federal Circuit noted that use of a generic computer to implement a "fundamental economic practice" cannot provide an inventive concept sufficient to save claims from patent ineligibility, and thus, this opinion does not create a genuine dispute of material fact.

    The Federal Circuit having reviewed the expert reports found that no reasonable factfinder could find, based on the expert reports, that the asserted claims are directed to patent-eligible subject matter.

    Thus, the Federal Circuit found the patent claims to be directed to patent-ineligible subject matter, and that the District Court's granting of summary judgment, even with dueling expert opinions alleging factual disputes, was proper.  It seems that patent owners attempting to survive a summary judgment challenge under § 101 should consider submitting expert reports from patent specialists, to tie any alleged improvement described in the specification to the asserted claims, as well as to offer expert opinion regarding how the asserted claims constitute "significantly more" so as to recite an "inventive concept".  Some genuine issue of material fact seems to be present in this case, but such issue was not presented in a detailed way that satisfied the Federal Circuit.

    That being said, it's hard to find some "inventive concept" in these claims.  Once the generic computer components are removed (none of which are asserted as new), what remains are a recitation of basic manual steps to find a loan.  Mortgage Grader was unable to show that these steps solved some problem, provided some improvement in the banking field, or improved operation of computers used for banking services that could give rise to any inventive concept.

    Mortgage Grader, Inc. v. First Choice Loan Services Inc. (Fed. Cir. 2016)
    Panel:  Circuit Judges O'Malley and Taranto, and Chief District Judge Stark (sitting by designation)
    Opinion by Chief District Judge Stark